Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J’s Rybrevant May Find Limited Uptake Outside Academic Centers

Potential For Post-Tagrisso Therapy Niche

Executive Summary

The lung cancer drug’s side effects may deter some community oncologists, while a potentially safer drug earlier in development could prove more attractive.

You may also be interested in...



J&J’s Rybrevant Results Provide Encouragement After Interim Analysis Sparked Jitters

The company announced topline results for MARIPOSA in EGFR-mutant NSCLC, showing positive progression-free survival and a favorable trend on overall survival.

J&J Rybrevant Update Could Bode Positively For AstraZeneca’s Tagrisso

A Phase III trial of Rybrevant with lazertinib versus Tagrisso in first line EGFR-positive NSCLC is continuing after an interim analysis, surprising some investors who thought it might be stopped early for efficacy.

Advanced Antibodies Will Revolutionize The Future Of IO

Immuno-oncology is a key area for biological drug development and activity has exploded over the past decade. Today, IO therapies represent a third of the biologics pipeline, and antibody development remains the focus.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC144411

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel